A COMPREHENSIVE REVIEW ON BALCINORENONE, ITS MECHANISM AND FUNCTIONALITY

Abstract

Balcinrenone represents a groundbreaking modulator of mineralocorticoid receptors that, as
indicated by early studies, maintains cardiovascular and renal benefits without raising the
likelihood of hyperkalemia. Its development is paired with dapagliflozin for the management of
heart failure in individuals with impaired kidney function and chronic kidney disease. The aim of
this research was to employ a population pharmacokinetic approach to define the pharmacokinetics
of Balcinrenone and evaluate how both internal and external factors influence its pharmacokinetic
behavior. An investigation into absorption, distribution, metabolism, and excretion was carried out
to establish essential pharmacokinetic parameters, mass balance, and metabolite profiles of
Balcinrenone in human subjects. This study was designed as an open-label, single-center,
nonrandomized trial with two distinct periods. In the first period, eight healthy male participants
were administered a microtracer intravenous infusion of Balcinrenone immediately after taking an
oral dose of unlabeled Balcinrenone in a capsule form. Following a washout period of seven days,
the same participants later received an oral suspension of Balcinrenone in the second period. The
clearance and absolute bioavailability of Balcinrenone were established at 14. 2 l/h and 52%,
respectively. The renal clearance rate was calculated at 5. 4 l/h, which indicates elimination
through active tubular secretion potentially facilitated by P-glycoprotein 1 and/or organic anion
transporter 3 based on in vitro transporter studies. A total of 94. 1% of the administered oral dose
was recovered, with 45. 2% found in urine and 48. 9% in feces. The primary metabolic pathway
of Balcinrenone involved oxidation, with in vitro evidence indicating that cytochrome P450 3A4
mainly drives this process. Unchanged Balcinrenone constituted 55% of the drug-related substance
in plasma, with four metabolites observed, none exceeding 6% of the overall plasma radioactivity.
In summary, this two-period investigation has established the fundamental pharmacokinetic
characteristics of Balcinrenone in humans, including absolute bioavailability and its disposition
profile. The identified metabolites did not require further investigation due to their minimal
presence, and their potential role in influencing pharmacodynamic responses or drug-drug
interactions was considered insignificant. Overactive mineralocorticoid receptor function is
associated with cardiovascular and renal disorders. Reducing MR activation through
mineralocorticoid receptor antagonists has proven effective in slowing the progression of chronic
kidney disease and its related cardiovascular complications in both animal research and patient
studies. This current investigation looks into the effects of the mineralocorticoid receptor
modulator Balcinrenone alongside the mineralocorticoid receptor antagonist eplerenone on kidney
injury within a metabolic chronic kidney disease mouse model that combines nephron reduction
with a high-fat diet consisting of 60%. Both Balcinrenone and Eplerenone showed similar
effectiveness in preventing the advancement of kidney injury, extracellular matrix changes, and
inflammation. A novel mechanism was identified that connects MR activation to the deposition of
renal proteoglycans and inflammation through the stimulation of the TLR4 pathway. Balcinrenone
and eplerenone were both effective in attenuating this pathway activation.